Stay updated on Ribociclib Efficacy After CDK4/6 Inhibit Progression Clinical Trial
Sign up to get notified when there's something new on the Ribociclib Efficacy After CDK4/6 Inhibit Progression Clinical Trial page.

Latest updates to the Ribociclib Efficacy After CDK4/6 Inhibit Progression Clinical Trial page
- Check6 days agoChange DetectedA consolidated Locations section with state site listings (Alabama, Georgia, Illinois, Kansas, New York, Tennessee, Wisconsin) was added and the per-state location subsections were removed. The HHS Vulnerability Disclosure link was removed.SummaryDifference0.8%

- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check28 days agoChange DetectedThe page now shows Revision: v3.3.2 (replacing v3.3.1). This is a versioning detail and does not affect the study details or functionality.SummaryDifference0.0%

- Check35 days agoChange DetectedRevision: v3.3.1 was added and Revision: v3.2.0 was removed.SummaryDifference0.0%

- Check42 days agoChange DetectedA banner containing a notice about government funding lapse and NIH operating status was removed from the page. The removed text directed users to cc.nih.gov and opm.gov and did not pertain to the study details.SummaryDifference0.3%

- Check56 days agoChange DetectedMAINTAIN (NCT02632045) results have been posted and the study status updated to Completed. Enrollment and site details reflect the final data.SummaryDifference0.4%

- Check85 days agoChange DetectedNew operating-status notice and v3.2.0 release; prior v3.1.0 revision removed.SummaryDifference2%

Stay in the know with updates to Ribociclib Efficacy After CDK4/6 Inhibit Progression Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ribociclib Efficacy After CDK4/6 Inhibit Progression Clinical Trial page.